Last updated: August 8, 2026
In re Mylan N.V. Securities Litigation was a putative securities-fraud class action in the U.S. District Court for the Southern District of New York concerning Mylan N.V.'s pricing, Medicaid-rebate treatment, and public disclosures for EpiPen and other products. The case was assigned to Judge J. Paul Oetken under docket number 1:16-cv-07926-JPO.
The plaintiffs alleged that Mylan misled investors about the classification of EpiPen under the Medicaid Drug Rebate Program, the resulting rebate obligations, the competitive position of EpiPen, and the sustainability of Mylan's revenue and earnings. The court dismissed the claims. The litigation did not involve patent infringement, Hatch-Waxman Paragraph IV litigation, biosimilar competition, or Orange Book-listed patents.
What was In re Mylan N.V. Securities Litigation about?
The action focused on alleged securities-law violations arising from Mylan's EpiPen pricing strategy and government-reimbursement disclosures.
Mylan marketed EpiPen, an epinephrine auto-injector used to treat severe allergic reactions. During the alleged class period, Mylan increased the U.S. list price of a two-pack from approximately $100 to more than $600. Public criticism intensified in 2016 after reports questioned the affordability of EpiPen and Mylan's treatment of the product under the Medicaid Drug Rebate Program.
The plaintiffs claimed that Mylan:
- Misclassified EpiPen for Medicaid-rebate purposes.
- Paid rebates applicable to generic drugs rather than higher rebates applicable to branded drugs.
- Failed to disclose the financial effect of the alleged classification.
- Misrepresented EpiPen's market position and competitive risks.
- Concealed the extent to which EpiPen revenue depended on price increases.
- Made misleading statements about Mylan's business, financial performance, and regulatory compliance.
The asserted claims arose primarily under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
What were the key dates in the Mylan securities case?
| Date |
Event |
| 2016 |
Mylan faced escalating public and governmental scrutiny over EpiPen pricing and Medicaid-rebate treatment. |
| October 2016 |
The securities action was filed in the Southern District of New York. |
| 2017 |
The court addressed amended pleadings and defendants' motion to dismiss. |
| March 29, 2018 |
Judge Oetken issued the principal dismissal decision in In re Mylan N.V. Securities Litigation, 2018 WL 1595980 (S.D.N.Y. Mar. 29, 2018). |
| After the dismissal order |
The claims were dismissed and the federal securities action did not proceed to trial. |
The case was filed under 1:16-cv-07926-JPO. Mylan N.V. was the principal issuer defendant. The litigation also named senior company executives and related defendants, as reflected in the pleadings and docket record.
What securities-law claims did investors assert against Mylan?
The plaintiffs asserted a fraud theory under Section 10(b) and Rule 10b-5, together with control-person claims under Section 20(a).
To state a Section 10(b) claim, the plaintiffs had to plead:
- A material misrepresentation or omission.
- Scienter.
- A connection with the purchase or sale of securities.
- Reliance.
- Economic loss.
- Loss causation.
Because the complaint alleged securities fraud, it also had to satisfy the heightened pleading standards under the Private Securities Litigation Reform Act and Federal Rule of Civil Procedure 9(b).
The Section 20(a) claims depended on an underlying primary securities violation. Once the Section 10(b) claims failed, the control-person claims also failed.
Why did the court dismiss the Mylan securities claims?
The court concluded that the complaint did not adequately plead actionable securities fraud under the federal pleading standards.
The decision addressed the alleged Medicaid-rebate misclassification, Mylan's statements about EpiPen and competition, and the company's public disclosures concerning its business and financial results. The court did not convert the dispute into a trial over whether Mylan's business practices were commercially controversial. The issue was whether the complaint adequately alleged a materially false statement, a duty to disclose, scienter, and a causal connection to investor losses.
Medicaid-rebate allegations
The plaintiffs argued that Mylan had an obligation to disclose that EpiPen was improperly treated as a generic product for Medicaid-rebate purposes. The court rejected or found insufficient the plaintiffs' theory that the challenged disclosures supported a securities-fraud claim.
A securities issuer does not have a general obligation to disclose every fact that could affect an investor's evaluation of the business. An omission becomes actionable when disclosure is required to make prior statements not misleading, when the issuer has a duty to disclose, or when the issuer makes a materially false statement.
The court treated the plaintiffs' allegations as insufficient to establish that Mylan's public statements were materially misleading under the applicable securities-law standards.
Statements about competition and EpiPen
The complaint challenged Mylan's descriptions of EpiPen's market position and competitive environment. The court found that the plaintiffs had not adequately shown that the challenged statements were materially false when made.
General statements about business performance, competition, market opportunity, or management expectations often fall outside the scope of actionable fraud unless the complaint identifies a specific false representation of existing fact. Forward-looking statements also receive protection when statutory safe-harbor requirements are satisfied.
Scienter
The plaintiffs had to plead facts giving rise to a strong inference that Mylan and the individual defendants acted with fraudulent intent or severe recklessness.
The court found that the complaint did not meet that standard. Allegations that executives knew the company's pricing and rebate practices, received compensation tied to financial performance, or sold stock generally were not enough without particularized facts connecting those events to fraudulent intent.
Loss causation
The complaint also had to connect the alleged fraud to the market loss suffered by investors. The plaintiffs relied on disclosures and public events concerning EpiPen pricing, regulatory exposure, and Medicaid rebates.
The court determined that the pleadings did not sufficiently establish that the alleged corrective disclosures revealed the specific fraud alleged in the complaint and caused the claimed stock-price decline.
What was the final outcome of the case?
The federal securities claims were dismissed at the pleading stage. The action did not proceed to a merits trial, damages phase, or jury verdict.
The principal reported district-court decision is:
In re Mylan N.V. Securities Litigation, No. 16 Civ. 7926 (JPO), 2018 WL 1595980 (S.D.N.Y. Mar. 29, 2018).
The result was favorable to Mylan and the individual defendants. The dismissal eliminated the asserted federal securities claims based on EpiPen pricing and Medicaid-rebate disclosures.
Was there a Mylan securities litigation settlement?
The case did not produce a publicly reported class-action settlement comparable to major pharmaceutical securities settlements. The operative result was dismissal rather than a negotiated damages resolution.
The litigation record should therefore be distinguished from:
- Government settlements involving EpiPen or Medicaid-rebate issues.
- Consumer class actions alleging improper EpiPen pricing.
- Antitrust litigation involving EpiPen or epinephrine auto-injectors.
- Patent litigation involving EpiPen delivery systems.
- Shareholder derivative actions involving Mylan corporate conduct.
Those matters may involve overlapping facts but are legally separate from docket 1:16-cv-07926-JPO.
Did the case involve Paragraph IV patent challenges?
No. In re Mylan N.V. Securities Litigation was not a Hatch-Waxman patent case.
The case did not concern:
- An Abbreviated New Drug Application.
- A Paragraph IV certification.
- An Orange Book patent dispute.
- A patent term calculation.
- A generic launch date.
- A preliminary injunction based on patent infringement.
- A settlement restricting generic entry.
The dispute involved securities disclosures and alleged investor harm. It therefore has no direct effect on generic-entry rights or patent exclusivity for EpiPen.
What was the FDA and Orange Book status relevant to this case?
The FDA and Orange Book were relevant only as commercial and regulatory background, not as the source of the claims.
EpiPen is a drug-device combination product consisting of epinephrine delivered through an auto-injector. The securities claims did not require the court to determine whether a particular patent was valid, infringed, or enforceable. The decision also did not establish the expiration date of any EpiPen patent or regulatory exclusivity period.
For market-analysis purposes, the following distinction is material:
| Issue |
Relevance to 1:16-cv-07926-JPO |
| EpiPen pricing |
Central factual background |
| Medicaid rebate classification |
Central legal and disclosure theory |
| FDA approval |
Background regulatory fact |
| Orange Book listing |
Not the cause of action |
| Patent infringement |
Not adjudicated |
| Paragraph IV challenge |
Not involved |
| Generic competition |
Relevant to alleged disclosures, not decided as a patent issue |
| Biosimilar competition |
Not applicable |
| Patent expiration |
Not decided |
How did the litigation affect Mylan's commercial exposure?
The case exposed Mylan to potential class-wide damages claims based on alleged inflation of Mylan's stock price during the proposed class period. The plaintiffs' theory was that investors paid more for Mylan securities because the market allegedly lacked material information about EpiPen's Medicaid-rebate treatment, pricing sustainability, regulatory risk, and competitive exposure.
The commercial risks included:
- Reputational damage from the EpiPen price controversy.
- Potential securities damages measured by stock-price inflation.
- Regulatory and reimbursement scrutiny.
- Possible follow-on government investigations.
- Increased attention to Mylan's pricing and disclosure controls.
- Pressure on future EpiPen revenue and gross margins.
The dismissal reduced the direct securities-litigation exposure associated with the pleaded facts. It did not eliminate business risks arising from public criticism, regulatory review, reimbursement disputes, product competition, or other litigation.
How strong was the plaintiffs' case?
The case presented a commercially significant narrative but a legally difficult securities claim.
The plaintiffs had facts capable of supporting investor concern:
- A substantial EpiPen price increase.
- Public controversy over affordability.
- Questions about Medicaid-rebate treatment.
- A subsequent decline in Mylan's market value.
- Allegations concerning executive knowledge and incentives.
The pleading weakness was the failure to convert those facts into a sufficiently particularized fraud claim. The court required a tighter connection between:
- A specific false statement.
- The facts known to defendants when the statement was made.
- A strong inference of fraudulent intent.
- A corrective disclosure.
- The resulting stock-price loss.
The decision illustrates the difference between evidence of aggressive pricing or potential regulatory exposure and evidence of actionable securities fraud. Business conduct can attract governmental or public criticism without satisfying the PSLRA's heightened pleading requirements.
What litigation risks remained after dismissal?
The dismissal of the securities case did not resolve every issue connected with EpiPen.
Potentially separate areas of exposure included:
Government reimbursement and regulatory matters
Medicaid classification and rebate obligations could generate government claims, reimbursement disputes, penalties, or compliance obligations independent of private securities litigation.
Consumer and antitrust claims
Consumers, payors, competitors, or governmental entities could pursue theories based on pricing, market conduct, distribution practices, or competition. Those claims would require different elements and evidence.
Product and manufacturing issues
EpiPen is a drug-device combination product. Product liability, manufacturing, quality, device-performance, and supply issues could create separate exposure.
Intellectual property disputes
Patent claims concerning auto-injector design, dose delivery, manufacturing, or competing products would be separate from the securities action. The securities decision provides no ruling on those patent rights.
How does this case compare with Mylan patent litigation?
| Category |
Mylan securities litigation |
Mylan patent litigation |
| Primary law |
Securities Exchange Act |
Patent Act and Hatch-Waxman |
| Typical claimant |
Investors |
Patent holder or generic applicant |
| Core issue |
Misleading disclosures and investor loss |
Validity, infringement, or enforceability |
| Key pleading standard |
PSLRA and Rule 9(b) |
Federal patent pleading rules |
| FDA role |
Factual and commercial background |
Central to ANDA and Orange Book disputes |
| Remedy |
Damages or other securities relief |
Injunction, damages, or launch rights |
| Generic launch impact |
Indirect |
Direct |
| Outcome in this case |
Dismissal |
No patent determination |
The securities decision should not be used to assess EpiPen patent strength, generic-launch timing, or the enforceability of any Mylan intellectual-property right.
What is the current legal significance of the case?
The case is significant for its treatment of pharmaceutical pricing disclosures, Medicaid-rebate allegations, and the PSLRA's particularity requirements.
For pharmaceutical companies, the decision supports several practical conclusions:
- Price increases alone do not establish securities fraud.
- Regulatory uncertainty does not automatically create a disclosure violation.
- A complaint must identify specific misleading statements and explain why they were false when made.
- Executive knowledge must be pleaded with particularized facts.
- Stock-price decline after public controversy does not by itself establish loss causation.
- A viable securities claim must distinguish between business criticism and fraud.
For investors, the decision shows the difficulty of pursuing securities claims based on a product-pricing controversy when the public record contains multiple possible causes for a stock decline.
Key Takeaways
- In re Mylan N.V. Securities Litigation, 1:16-cv-07926-JPO, was a Southern District of New York securities class action concerning EpiPen pricing and Medicaid-rebate disclosures.
- The case was not a patent, Orange Book, Paragraph IV, biosimilar, or generic-launch dispute.
- Plaintiffs asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5.
- The court dismissed the claims in a March 29, 2018 decision.
- The court found the pleadings insufficient under the PSLRA's standards for falsity, scienter, and loss causation.
- The action did not result in a publicly reported class settlement or trial judgment.
- The decision did not determine the validity, expiration, or enforceability of any EpiPen patent.
- Separate regulatory, consumer, antitrust, reimbursement, product, and intellectual-property risks were not resolved by the dismissal.
FAQs About In re Mylan N.V. Securities Litigation
What was the class period in the Mylan EpiPen securities case?
The action concerned Mylan's public disclosures during the period surrounding the EpiPen pricing controversy and the market's reaction in 2016. The operative pleadings defined the proposed class period.
Who was the judge in the Mylan securities litigation?
Judge J. Paul Oetken of the U.S. District Court for the Southern District of New York presided over the case.
Did Mylan admit securities fraud in the EpiPen case?
No. The case ended through dismissal of the pleaded securities claims, not through an admission of fraud.
Did the Mylan case establish that EpiPen was misclassified under Medicaid rules?
No. The court's securities decision did not constitute a final determination that EpiPen was improperly classified for Medicaid-rebate purposes.
Can the Mylan decision be cited in a generic EpiPen patent analysis?
Only for the limited proposition that the case was unrelated to patent rights. It does not establish EpiPen patent expiration, Orange Book coverage, Paragraph IV risk, or generic launch timing.
References
-
U.S. District Court for the Southern District of New York. (2018, March 29). In re Mylan N.V. Securities Litigation, No. 16 Civ. 7926 (JPO), 2018 WL 1595980.
-
United States Congress. (1995). Private Securities Litigation Reform Act of 1995, Pub. L. No. 104-67, 109 Stat. 737.
-
U.S. Securities and Exchange Commission. (n.d.). Securities Exchange Act of 1934, Section 10(b) and Rule 10b-5.
-
U.S. Securities and Exchange Commission. (n.d.). Securities Exchange Act of 1934, Section 20(a).
